← Who reports today · Health Care
How McKesson (MCK) makes money: Q1 FY2027 revenue breakdown
This is the previous report. The new report for Q2 FY2027 came out on Nov 4, 2026 — breakdown in progress
Net Income (consolidated)
$1,032M
up 24.2% y/y
Revenues
$105,380M
up 7.7% y/y
Operating Income
$1,319M
up 27.3% y/y
New report
out Nov 4
breakdown in progress
The quarter in brief
The distributor's razor-thin machine ran faster and better — revenue +8%, operating income +27%, adjusted EPS +20% — while the headline 22% drop in net income to shareholders is accounting noise: a one-time $293M redemption-value adjustment for the Medical-Surgical minority stake sold to Apollo ahead of the Wellverse spin-off.
Key growth driver: Oncology & Multispecialty — the fastest-growing revenue line: $14,200, +33% y/y. · by the Q1 FY2027 report
How does McKesson make money?
McKesson brought in $105 billion of revenue in Q1 FY2027, up 7.7% year over year. The largest source was North American Pharmaceutical: ≈$86.8 billion, or 82% of the total, followed by Oncology & Multispecialty (≈$14.2B, 13%) and Medical-Surgical (≈$2.78B, 3%); other lines add the remaining 2%. Net income for the quarter was $1.03 billion, up 24.2% year over year.
Revenue by source, Q1 FY2027
- North American Pharmaceutical≈$86.8B · 82% · +5%
- Oncology & Multispecialty≈$14.2B · 13% · +33%
- Medical-Surgical≈$2.78B · 3% · +4%
- Prescription Tech≈$1.60B · 2% · +9%
Shares of $105B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| North American Pharmaceutical ≈ | $86,800 · +5% |
| Oncology & Multispecialty ≈ | $14,200 · +33% |
| Prescription Tech ≈ | $1,600 · +9% |
| Medical-Surgical ≈ | $2,780 · +4% |
| Revenues | $105,380 · +7.7% |
| Cost of Sales | $101,695 · +7.6% |
| Gross Profit | $3,685 · +12.4% · 3.5% margin |
| Selling, Distribution, G&A | $2,264 · +3.1% |
| Restructuring & Impairment | $136 · vs $47 |
| Litigation Credit, net | $34 · vs $0 |
| Operating Income | $1,319 · +27.3% · 1.25% of revenue |
| Other Income, net | $66 · +3.1% |
| Interest Expense | $77 · +57% |
| Pre-Tax Income | $1,308 · +24.4% |
| Income Tax | $276 · ETR 21.1% |
| Net Income (consolidated) | $1,032 · +24.2% |
| Noncontrolling Interests (incl. $293M adj.) | $418 · vs $47 |
| Net Income to Shareholders | $614 · -21.7% · adjusted EPS +20% |
Verdict: the distributor's razor-thin machine ran faster and better — revenue +8%, operating income +27%, adjusted EPS +20% — while the headline 22% drop in net income to shareholders is accounting noise: a one-time $293M redemption-value adjustment for the Medical-Surgical minority stake sold to Apollo ahead of the Wellverse spin-off.
Quarter used $220M of operating cash (seasonal working capital; FCF −$372M); returned $2.6B to shareholders ($2.5B buybacks incl. ASR). Dividend raised 15% to $0.94/sh — tenth consecutive annual increase. FY2027 adjusted EPS guidance raised to $44.20-45.00.
Source and notation
* marks non-cash / ≈ estimated. Segment revenues are press-release approximations. Source: McKesson press release 8-K EX-99.1 (SEC EDGAR).
Open as an image: McKesson (MCK), Q1 FY2027 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “McKesson (MCK) Q1 FY2027: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mck. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/mck"><img src="https://whoreportstoday.com/t/mck/img/mckesson-mck-earnings-sankey.png" alt="McKesson (MCK) Q1 FY2027: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/mck">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/mck/img/mckesson-mck-earnings-sankey.png
<a href="https://whoreportstoday.com/t/mck">McKesson (MCK) Q1 FY2027 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- The Sankey's shape IS the business model: $101.7B of $105.4B revenue flows straight through to cost of drugs — a 3.5% gross margin on which McKesson still compounds double-digit profit growth.
- Attributable net income fell 22% for a one-time reason: a $293M redemption-value adjustment on redeemable noncontrolling interests after selling ~13% of Medical-Surgical Solutions to Apollo Funds for $1.25B — the future 'Wellverse' spin-off (unveiled 08/05/2026).
- The year-ago quarter had its own one-off in the other direction: a $189M bad-debt provision tied to the Rite Aid bankruptcy — underlying growth is cleaner than either headline.
- Oncology & Multispecialty is the growth engine: revenue +33% to $14.2B with adjusted segment profit +41%; core NA Pharmaceutical grew 5% with adjusted profit +19%.
- Claims and litigation was a rare CREDIT of $34M this quarter (opioid-era charges reversing at the margin); restructuring/impairment tripled to $136M.
- Negative free cash flow of −$372M is normal Q1 seasonality for a drug distributor (working-capital build); the company still bought back $2.5B of stock in the quarter.
- Diluted share count fell 5% y/y — the buyback engine adds ~5 points to per-share growth every year.
- Interest expense jumped 57% to $77M, partly the new $2.25B Term Loan B raised to fund the Medical-Surgical separation.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Brian S. TylerChief Executive Officer [1]
- Kenny K. CheungExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- McKessonsince 2012
- Chief Executive Officer and Directorsince 2019
- President and Chief Operating Officer2018–2019
- President of North America Distribution and Services2015–2016
- Executive Vice President, Corporate Strategy and Business Development2012–2015
- McKesson Europe2016–2018
- Chairman of the Management Board2017–2018
- President and Chief Operating Officer2016–2017
Source: SEC EDGAR: 10-K annual report, 2026-05-08 · as of 10/21/2026
- McKessonsince 2026Executive Vice President and Chief Financial Officer
- Sysco2023Executive Vice President and Chief Financial Officer
- Hertz2018–2023
- Chief Financial Officer2020–2023
- Senior Vice President of Global FP&A and CFO of Hertz North America2018–2019
- NielsenOperational and finance leadership positions
1 more
- Financial Management Program
Source: SEC EDGAR: 8-K (appointment), 2026-03-05 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2027 | EPS (non-GAAP) $45.60–46.40 (raised) | revenue $403.4BEPS (GAAP) $38.38 | — |
Same quarter a year ago (ended December 31, 2025): revenue $106.2B, EPS (GAAP) $9.59
How we calculate
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Nov 4, 2026); every figure is checked against the release text.
MCK earnings history: past report dates
| Nov 4, 2026 Wed | 4:06 pmafter market close | Sep 30, 2026 | $111B+8% y/y | $10.44+17% y/y |
| Aug 5, 2026 Wed | 4:06 pmafter market close | Jun 30, 2026 | $105B+8% y/y | $5.15−18% y/y |
| May 7, 2026 Thu | 4:07 pmafter market close | Mar 31, 2026 | ≈$96.3B+6% y/y | ≈$13.62+38% y/y |
| Feb 4, 2026 Wed | 4:05 pmafter market close | Dec 31, 2025 | $106B+11% y/y | $9.59+38% y/y |
| Nov 5, 2025 Wed | 4:05 pmafter market close | Sep 30, 2025 | $103B+10% y/y | $8.92+377% y/y |
| Aug 6, 2025 Wed | 4:06 pmafter market close | Jun 30, 2025 | $97.8B+23% y/y | $6.25−11% y/y |
| May 8, 2025 Thu | 4:06 pmafter market close | Mar 31, 2025 | ≈$90.8B+19% y/y | ≈$9.90+64% y/y |
| Feb 5, 2025 Wed | 4:05 pmafter market close | Dec 31, 2024 | $95.3B+18% y/y | $6.95+57% y/y |
| Nov 6, 2024 Wed | 4:05 pmafter market close | Sep 30, 2024 | $93.7B+21% y/y | $1.87−62% y/y |
| Aug 7, 2024 Wed | 4:05 pmafter market close | Jun 30, 2024 | $79.3B+6% y/y | $7.00−0% y/y |
| May 7, 2024 Tue | 4:05 pmafter market close | Mar 31, 2024 | ≈$76.4B+11% y/y | ≈$6.03+5% y/y |
| Feb 7, 2024 Wed | 4:05 pmafter market close | Dec 31, 2023 | $80.9B+15% y/y | $4.42−42% y/y |
| Nov 1, 2023 Wed | 4:05 pmafter market close | Sep 30, 2023 | $77.2B+10% y/y | $4.92−23% y/y |
| Aug 2, 2023 Wed | 4:05 pmafter market close | Jun 30, 2023 | $74.5B+11% y/y | $7.02+33% y/y |
| May 8, 2023 Mon | 4:05 pmafter market close | Mar 31, 2023 | ≈$68.9B+4% y/y | ≈$5.73+135% y/y |
Show all 15 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
McKesson: 16-year financials
| FY2026 | 403,430 | 6,212 | 4,762 | 5,719 | 381 |
| FY2025 | 359,051 | 4,422 | 3,295 | 5,548 | 345 |
| FY2024 | 308,951 | 3,909 | 3,002 | 3,883 | 314 |
| FY2023 | 276,711 | 4,381 | 3,560 | 4,769 | 292 |
| FY2022 | 263,966 | 2,038 | 1,114 | 4,046 | 277 |
| FY2021 | 238,228 | −5,040 | −4,539 | 4,091 | 276 |
| FY2020 | 231,051 | 2,489 | 900 | 4,012 | 294 |
| FY2019 | 214,319 | 886 | 34 | 3,610 | 292 |
| FY2018 | 208,357 | 762 | 67 | 3,940 | 262 |
| FY2017 | 198,533 | 7,122 | 5,070 | 4,340 | 253 |
| FY2016 | 190,884 | 3,545 | 2,258 | 3,184 | 244 |
| FY2015 | 179,045 | 2,968 | 1,476 | 2,736 | 227 |
| FY2014 | 137,392 | 2,439 | 1,263 | 2,858 | 214 |
| FY2013 | 122,196 | 2,347 | 1,338 | 2,242 | 194 |
| FY2012 | 122,321 | 2,124 | 1,403 | 2,729 | 195 |
| FY2011 | 112,084 | 1,821 | 1,202 | 2,105 | 171 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The company’s fiscal year doesn’t match the calendar year, so years follow the company’s own labels. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
McKesson: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2026 | 82,323 | −2,172 | 6,526 | 3,975 | 57,210 | 67,017 |
| 2025 | 75,140 | −2,074 | 5,654 | 5,691 | 55,398 | 61,604 |
| 2024 | 67,443 | −1,971 | 5,629 | 4,583 | 47,970 | 52,357 |
| 2023 | 62,320 | −1,857 | 5,594 | 4,678 | 44,292 | 47,957 |
| 2022 | 63,298 | −2,272 | 5,879 | 3,532 | 46,231 | 48,466 |
| 2021 | 65,015 | −21 | 7,148 | 6,278 | 45,382 | 44,103 |
| 2020 | 61,247 | 5,092 | 7,387 | 4,015 | 42,222 | 42,624 |
| 2019 | 59,672 | 8,094 | 7,595 | 2,981 | 38,465 | 37,626 |
| 2018 | 60,381 | 9,804 | 7,880 | 2,672 | 37,136 | 36,685 |
| 2017 | 60,969 | 11,095 | 8,545 | 2,783 | 36,948 | 35,612 |
| 2016 | 56,523 | 8,924 | 8,114 | 4,048 | 38,435 | 35,069 |
| 2015 | 53,870 | 8,001 | 9,844 | 5,341 | 36,670 | 33,497 |
| 2014 | 51,759 | 8,522 | 10,594 | 4,193 | 32,836 | 29,615 |
| 2013 | 34,786 | 7,070 | 4,873 | 2,456 | 23,170 | 21,357 |
| 2012 | 33,093 | 6,831 | 3,580 | 3,149 | 23,603 | 21,686 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
6 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 2,850 | 1,502 | +1,348 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 139 | 124 | |
| Capexpurchases of property & equipment | −177 | −217 | +40 |
| Free cash flow ≈operating cash flow − capex | 2,673 | 1,285 | +1,388 |
| Investing activities, netcapex, acquisitions, securities | −344 | −3,588 | +3,244 |
| · incl. acquisitionsbusinesses net of cash acquired | −23 | −3,389 | +3,366 |
| Financing activities, netdebt, buybacks, dividends | 58 | 215 | −157 |
| · incl. buybacksrepurchases of common stock | −3,424 | −1,399 | −2,025 |
| · incl. dividends paid | −198 | −179 | −19 |
| FX effect on cash | −13 | 24 | −37 |
| Net change in cash | 2,551 | −1,847 | +4,398 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: −$4.0B (−4.3% of total assets). Other S&P 500 companies with negative equity →
Corporate governance
1.5/2mostly good
- May 2023McKesson settled the Evanston Police Pension Fund shareholder class action (earnings inflated in 2013–2017 by a generic-drug price-fixing conspiracy) for $141M, paid by insurers in February 2023. sec.gov ↗
- May 2026FY2026 10-K: a single class of common stock; diluted share count −22.7% over 5 years, dividend up from $1.67 to $3.17. sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Jun 20262026 proxy: there were no reportable related-party transactions in FY2026. sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: Evanston shareholder class action over concealed generic-drug price fixing settled for $141M, 2022–2023) = 1.5
- Share classes
- Single class — MCK common stock on the NYSE (cover of FY2026 10-K); everything else is notes.
- Dilution
- Diluted share count FY2021→FY2026 −22.7% (XBRL); SBC 0.1% of revenue.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- Dividend raised every year: $1.67 (FY2021) → $3.17 (FY2026); buybacks of $3–4.8B a year.
- Lawsuits & regulators
- Evanston Police Pension Fund suit (10(b), 2018) settled for $141M (insurance-funded, no admission) → −0.5; the HBOC suits (settled 2005–2006) are older than 15 years and not counted; opioid settlements are not shareholder suits — no deduction.
- Related parties
- 2026 proxy: "there were no reportable related-party transactions in FY2026."
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · S&P 500 companies that paid dividends 10 years without a gap · S&P 500 companies shrinking their share count
McKesson (MCK) earnings: FAQ
How does McKesson make money?
McKesson brought in $105 billion of revenue in Q1 FY2027, up 7.7% year over year. The largest source was North American Pharmaceutical: ≈$86.8 billion, or 82% of the total, followed by Oncology & Multispecialty (≈$14.2B, 13%) and Medical-Surgical (≈$2.78B, 3%); other lines add the remaining 2%. Net income for the quarter was $1.03 billion, up 24.2% year over year.
When is MCK's next earnings date?
We have not yet seen an announcement of the date from McKesson (MCK). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.
What time does MCK report earnings?
McKesson usually reports after market close: its latest results release was filed with the SEC at 4:06 pm ET on Nov 4, 2026.
When did MCK last report earnings?
McKesson reported Q1 FY2027 results on Aug 5, 2026.
What has McKesson guided for FY2027?
Company guidance for FY2027: EPS (non-GAAP) $45.60–46.40 (raised). A year ago (FY2026): revenue $403.4B, EPS (GAAP) $38.38. Source: the company's earnings release (Form 8-K filed Nov 4, 2026).
Where can I find McKesson's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to MCK's filings; this page breaks the latest report down in a Sankey chart.
What was MCK's net income in Q1 FY2027?
McKesson reported net income of $1,032M for Q1 FY2027 (+24.2% year over year), under US GAAP.
Does McKesson pay dividends?
Yes. In fiscal 2026, McKesson paid $381M in dividends on its common stock, per its 10-K. Earlier years are in the 16-year table above.
How has McKesson's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.6x: $112,084M in fiscal 2011 and $403,430M in fiscal 2026. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · all reports